Amylyx Pharmaceuticals Other Current Liabilities

Amylyx Pharmaceuticals (AMLX) currently reports a other current liabilities of $15M as of June 2026. That compares with $17M in the prior-year period — down 16.4% year over year. Use the charts on this page to explore Amylyx Pharmaceuticals's other current liabilities history and peer comparisons.

Amylyx Pharmaceuticals's other current liabilities decreased from $17M to $15M — a 16.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Amylyx Pharmaceuticals reported $15M in other current liabilities as of June 2026. That compares with $17M in the prior-year period — down 16.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $15M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Amylyx Pharmaceuticals, and consider following AMLX for alerts when major investors trade the stock.